

data PROTO.PROTOCOL_TS;

infile datalines dlm = '|' missover;

input TS_VARIABLES : $20. TS_EXAMPLE : $40. TS_EXPLAIN : $40.;

datalines;
STUDYID|DIABETESA001|STUDY IDENTIFIER
SITEID|S00|TRIAL S00
TITLE|DIABETES TREATMENT EFFICIENT EVALUATION TRIAL |TRIAL TITLE
PHASE|2|TRIAL PHASE
STARTDATE|2024-12-01|TRIAL START DATE
ENDDATE|2025-07-31|TRIAL END DATE
PRIMARYPURP|TREATMENT OF DIABETES|TRIAL PRIMARY PURPOSE
DESIGN|Randomized, Double-Blind, Placebo-Controlled|TRIAL DESIGN
SUBJECTS|100|SAMPLE SIZE
PRIMARYEND|HbA1c CHANGE AT 7 Months|PRIMARY EVALUATION VALUE
SECONDEND|Fasting glucose|SECOND EVELUATION VALUE
;
run;


data SDTM.SDTM_TS;

infile datalines dsd dlm = '|' missover;

input STUDYID : $20. DOMAIN : $4. TSPARMCD : $8. TSPARM : $40. TSVAL : $200. TESCDREF : $40.;

datalines;
DIAA-2025-001|TE|ADDON|Added on to Existing Treatments|N|CDISC
DIAA-2025-001|TE|AGEMAX|Planned Maximum Age of Subjects|80|ISO 8601
DIAA-2025-001|TE|AGEMIN|Planned Minimum Age of Subjects|18|ISO 8601
DIAA-2025-001|TE|LENGTH|Trial Length|P7M|ISO 8601
DIAA-2025-001|TE|PLANSUB|Planned Number of Subjects|100|
DIAA-2025-001|TE|SEXPOP|Sex of Participants|BOTH|CDISC CT
DIAA-2025-001|TE|STOPRULE|Study Stop Rules|Trial stops if serious adverse events > 80%|CDISC CT
DIAA-2025-001|TE|TBLIND|Trial Blinding Schema|DOUBLE-BLIND|CDISC CT
DIAA-2025-001|TE|TCNTRL|Control Type|PLACEBO|CDISC CT
DIAA-2025-001|TE|TITLE|Trial Title|DIABETES TREATMENT EFFICIENT EVALUATION TRIAL|
DIAA-2025-001|TE|TPHASE|Trial Phase Classification|Phase II Trial|CDISC CT
DIAA-2025-001|TE|TTYPE|Trial Type|EFFICACY|CDISC CT
DIAA-2025-001|TE|OBJPRIM|Trial Primary Objective|Assess 7-month HbA1c reduction compared with control|
DIAA-2025-001|TE|SPONSOR|Clinical Study Sponsor|TEST_INST|
DIAA-2025-001|TE|REGID|Registry Identifier|TEST001|
DIAA-2025-001|TE|OUTMSPRI|Primary Outcome Measure|HbA1c|
DIAA-2025-001|TE|OUTMSSEC|Secondary Outcome Measure|GLUCOSE|
DIAA-2025-001|TE|FCNTRY|Planned Country of Investigational Sites|KOR|ISO 3166-1 Alpha-3
DIAA-2025-001|TE|ADAPT|Adaptive Design|N|CDISC
DIAA-2025-001|TE|DCUTDTC|Data Cutoff Date|2025-07-31|ISO 8601
DIAA-2025-001|TE|DCUTDESC|Data Cutoff Description|PRIMARY ANALYSIS|
DIAA-2025-001|TE|NARMS|Planned Number of Arms|2|
DIAA-2025-001|TE|STYPE|Study Type|INTERVENTION|CDISC CT
DIAA-2025-001|TE|INTTYPE|Intervention Type|DRUG|CDISC CT
DIAA-2025-001|TE|INTTYPE|Intervention Type|PLACEBO|CDISC CT
DIAA-2025-001|TE|SSTDTC|Study Start Date|2024-12-01|ISO 8601
DIAA-2025-001|TE|SENDTC|Study End Date|2025-07-31|ISO 8601
DIAA-2025-001|TE|ACTSUB|Actual Number of Subjects|100|
DIAA-2025-001|TE|HLTSUBJI|Healthy Subject Indicator|N|CDISC CT
;
run;


/*ADAPT(Adaptive Design): 시험 도중에 중간 데이터를 반영하는 설계 디자인*/
/*ADDON(Add-on-trial): 기존 치료에 추가하는 시험인지 아닌지 확인*/
/*NARMS(Number of Arms): ARM(투여군, 시험군) 개수*/
